Table 4. Sensitivity analysis: NHS and Societal perspective.

NHS perspective	N. HBV infection avoided	Net costs (1991–2010)	Net costs (1991–2059)	ROI (1991–2010)	ROI (1991–2059)
Baseline results	126,892	-11,021,153	-1,166,762,417	1.02	2.78
Adolescent vaccination coverage (95%)	126,892	5,268,429	-1,150,472,835	0.99	2.71
> % symptomatic subjects (+10%)	88,351	128,629,092	-676,047,683	0.80	2.03
Median age of chronic evolution (36 y)	126,892	-11,021,153	-1,080,801,052	1.02	2.65

Societal perspective	N. HBV infection avoided	Net costs (1991–2010)	Net costs (1991–2059)	BCR (1991–2010)	BCR (1991–2059)
Baseline results	126,892	81,402,035	-1,278,586,719	0.91	2.47
Adolescent vaccination coverage (95%)	126,892	109,211,314	-1,250,777,440	0.88	2.39
> % symptomatic subjects (+10%)	88,351	245,709,317	-701,172,609	0.72	1.80
Median age of chronic evolution (36 y)	126,892	81,402,035	-1,177,470,063	0.91	2.35